Publications by authors named "Birgit Edlich"

Background/aim: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment.

Patients And Methods: A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed.

Results: A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively.

View Article and Find Full Text PDF

Micro-abstract: In a Phase I dose-finding study of metronomic daily oral vinorelbine in advanced non-small-cell lung cancer, a recommended dose was established for this therapeutic approach. In addition, this trial revealed promising efficacy data and an acceptable tolerability profile. The observed vinorelbine blood concentrations suggest continuous anti-angiogenic coverage.

View Article and Find Full Text PDF

Background: Concurrent chemoradiotherapy (CRT) is considered standard for inoperable stage III non-small cell lung cancer (NSCLC). Consolidation chemotherapy (CC) following CRT is intended to further improve outcomes, yet studies have shown discordant results. This phase III study assessed CRT followed by best supportive care (BSC) or consolidation with oral vinorelbine and cisplatin.

View Article and Find Full Text PDF

Objective: Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C.

Design: 70 treatment-naive patients were randomised to 4 weeks of ribavirin (1000-1200 mg/d) or none, followed by PEG-IFNα-2a and ribavirin at standard doses and durations.

View Article and Find Full Text PDF

Unlabelled: Natural killer (NK) cells exhibit a polarized phenotype with increased cytotoxicity and decreased interferon gamma (IFN-γ) production in chronic hepatitis C virus (HCV) infection. Here, we asked whether this is caused by type I interferon (IFN)-induced expression and phosphorylation levels of signal transducer and activator of transcription (STAT) molecules in NK cells and whether it affects the response and refractoriness of NK cells to IFN-α-based therapy of HCV. STAT1 levels in NK cells were significantly higher in patients with chronic HCV infection than in uninfected controls.

View Article and Find Full Text PDF

Background & Aims: Mathematical modeling of hepatitis C virus (HCV) kinetics indicated that cellular immune responses contribute to interferon (IFN)-induced clearance of HCV. We investigated a potential role of natural killer (NK) cells in this process.

Methods: Phenotype and function of blood and liver NK cells were studied during the first 12 weeks of treatment with pegylated IFN-alfa and ribavirin, the time period used to define the early virological response.

View Article and Find Full Text PDF

Antigen-specific T cells can be induced by direct priming and cross-priming. To investigate cross-priming as a vaccination approach dendritic cells were transfected with cytopathogenic viral RNA-replicons that expressed domains of the tumor-associated Her2-antigen and injected into MHC-discordant mice that did not allow direct priming. Upon tumor challenge 75% of the vaccinated, but none of the mock-vaccinated mice remained tumor-free.

View Article and Find Full Text PDF

Background & Aims: Patients with chronic hepatitis C virus (HCV) infection display great variability in disease activity and progression. Although virus-specific adaptive immune responses have been characterized extensively and found to be impaired in chronic hepatitis C, the role of innate immune responses in disease activity and progression of chronic hepatitis C is not well understood.

Methods: We studied 42 HCV-infected patients and 12 healthy uninfected controls.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Birgit Edlich"

  • - Birgit Edlich's research primarily focuses on the fields of oncology and virology, particularly investigating therapeutic approaches for various cancers, such as non-small cell lung cancer, as well as understanding immune responses in chronic hepatitis C.
  • - Key findings include the establishment of a recommended dose and promising efficacy for metronomic oral vinorelbine in treating advanced non-small-cell lung cancer, and insights into the role of natural killer cells in the immune response to hepatitis C, highlighting differences in function and signaling pathways.
  • - Edlich has contributed to the understanding of combination therapies in cancer treatment, such as the efficacy of vinflunine combined with traditional chemotherapy, and explored antiviral treatments' mechanisms in chronic viral infections, which may help tailor more effective patient-specific therapies.